47�� !"# $%&

�� ! "#$%&'()*+,-./01 2

�� 1,2�� !1,3�� !1�� !4

�� 5,7�� !6,7

�� !"#$%%&'()*+,-./+01234*%567849

�� !"#$%&'()*"#+,-./&0123456789:;<-=>?+,8@A

��� �!"#$%&'()*+,-./0123456 �789(Lake Louise Acute Mountain

Sickness Score, LLAMSS) �� !"#$%&'()*+,-./!"#$0'123!"#(High Al-

titude Syndrome, HAS)�� !"#$%&'()*"+,-.,/0123,456789'$%:;

�� !"#$%& (Acute Mountain Sickness, AMS)�� !"#$%&'()*+,-./01234

�� !"#$%&'()*+P�� 0.05�� !"#$%&'(

�� 26�� !"#$29��70�� !"45.88�9.7�� !14�� !12�� !26�� !

�� !"#1000�� !"#21�(80.8%)�� !"#$%%&(HAS)��9�(34.6%)�� !"#$

�� !"#$%(SpO2)�� !"#$%&'()*+,SpO

2�� 84.19�5.39%�� !"#$%&

�SpO2�� !"#$%&'()*+,-. '(P=0.047)�� !"#$%&'()*+,-./

�� !"#$SpO2�� !"1%�� !"#$%HAS�AMS�� !"#$%&'1.8�2.0��

�� !"#$%&'()*+,,-./34.6%�� !"#$%&'80.8%�� !""#$%

�� !"SpO2�� 84.19%�SpO

2�� !"#$%&'()*+,-./0 12340 567

�� !"#$%

�� !"#$%&'()*+,'-%'$%.

�� 94�4�28�� !"#$94�11�28�1�� !"#$%&'#()*+#,-./2�� !"#$%&'()*+3�� !"#$%&'()*4�� !"#$%&#'(�� !"#)*+&,$%-.5�� !"#$%&'()*+6�� !"#$%&#'()*+,-&.$%/07�� !"#$%

�� !"#$%&'()*+,-./01201�� !"#$%&'()

�� (02)28757628�� !(02)28757842

E-mail: wfkao@vghtpe.gov.tw

��

�� !"#$%&'()*+,#-./

�� !"#$%&'�()*+,-./0(

�� !"#$%&'()*+,-./01&

�� !"#1921�� !"#$%&'()*

�� !"#$%&'(&)32�� !"#$

�� !"#$%&'()*+�,-./&0

� 1953�� !"#$%&'() (Edmund

Hil la ry)�� !"#$%&'()*+,

(Tenzing Norgay)�� !"#$%&'()�*

�� !"#$%&'(1)�� !"#$%&'(

�� !"#$%&'()*+,-.(�� !

�)�� !"#$ (��3952��)�� !"

�� !"#$%&'(

�� !"#$%&'3508�� !"!

J Emerg Crit Care Med. Vol. 17, No. 2, 200648

�� 79%�� !"#(2)�� 3650�� !"

�� !"#$�%(acute mountain sickness,

AMS)�� !34%(3)�� !"#$%&'()

��2000�� !"#$%&'%()*+,-

�� !"#$%&'()(��3050��)��

�� !"#$%&'()58%�� !"#$

�� !"(4)�� Roeggla�� !"Hackett�s

�� !"#�$%&'()*+,-.(5)��

�� !"#$%�&4200�� !6194��

�� !"#(Mt. McKinley)�� !"#$%&

�� !"#$%&'()*�+,-((6)��

�� !"#$%&'()$*%+,-%./

�� !"#$%&'()*+,(7)�� !"#

��� !"#$%&'()*+,-./01

�� !"#$%&'()*!+,-./01

�� !"#$%&'()*+,-./012

�� !

�� !"#$%&'()*+,$(-.

�� !"#$%&'( )*+,-./01

�� !"#$%�� &'()*+,#-.

�� !"#$%&'()*+,�� -./

�� !"#$%&'()*+��, !-

�� !"#$%&'()*+,�-./01

�� !"#$%&''((8)�� !"#$%&

�� !"#$%&'()*+,-./012

�� !"#$%&

�� !"

�� !"#$%&'()*+,-.�/

�� !"#$%&'�()�*(�� !"#

�� !"#$%&)�� !"2002�11�15�

11�17��26�� !"�#$%&10�� !

�� SpO2�� !"#$%&'()� !"

�� !"#$%&'(")*+,-./01

��(Lake Louise Acute Mountain Sickness Score,

LLAMSS) �� !"#$%&(9)�� !"#$

�� !"#$%&'(&)*+,-&./0

�� !"#$%&'()*+,-./&01

�� !"#$%&'()*+,-%&'(High

Altitude Syndrome, HAS)�� !"#$%&'

�0,1,2,3,4�� 0�� !"#$%1�� !"

�� !"#$%&'2�� !"#$%&'(

�� 3�� !"#$%&'()$*+,-.

4�� !"#$%&'()(10,11)�� !"#$

�� !"#$%&'()*+,-./012

�� !

�� ! �� !"#$%&'((�1�7

�) �� !"#(�10��11�)�� Nellcor

Puritan Bennett (NPB)�� !"#NPB40��

�� !" SpO2(�� !"#!$"%&

�)�� !"#$%&'()(�� !" #

�� !�"#�$%&�'&�()*+,)�

�� !(�� !"#$%#!&#'(#)

�� !"#�$%&'�()�*+�,-.

�� !�"#$%&'()) �� !(��

�� SpO2)�� !

�� !"#$%��(prospective study)�

�� !"#$%&'()*+,-./#01

�� !"#$%&'()*+� ,-./+

�� !"#$%& '()*+,-./01

�� !"#$%&'((�� )�� !"#$

�� !"#$%&'()*+,-./01+

�� !"#$%&'()*+,-./&01

�� !"#$%&'()!*+,-./01

�� !"#$%&'()!"�*+,-./

�� !"#$%&'()

�� !"#$%&'(�)*+,-./

�� !"#Student t test�� !"#$%&'

�� !"#$%&'()*+,- (logistic

regression)�� !"#$%&'()*+,-

SAS 8.0�� !"#$P�� 0.05�� !"#

�� !"#

�� !

�� !"#$%&'()*+',1��

�� !"#$%&'()�*+,-./01

�� !"#$%&'()*$+,-./01

�� !"#$%&'()*+,-./012

�� !"#$%&'()*+,-./012

�� !"#$%&'(

49�� !"# $%&

26�� !"#$%&'()29��70��

�� !"45.88�9.7�� !"#$%1000��

�� 26�� !"#$%&'()*+,-.

�� !"#�$%&'()*17��65%��

�� !"9��35% (��)�26�� !"#$

�21�(80.8%)�� !"#$%(HAS)�� 9�

(34.6%)�� !"#$%&'()*+,

�� !"#$%&'()*+,-.97%

�100%�� !"#$%98.5�0.86%�� !

��(��3402��)�� !"#$%87.58�

4.33%�� !"�(3952��)�� !"#$

72%�96%�� !"#$%84.19�5.39%��

�� !"#$%(��)�� !"#$%&'(

�� !�� !"#$%&!'()*+,-.

��HAS�� !"#$%(P=0.047�P=0.0199�

��)�� !"#$%&'()*+,-./0

�� !"#$%&'()*+!,-.1%��

�� !"#�� (HAS)�� !"#(AMS)�

�� !"#$%&1.83�2.00�(��)�

��

�� !"#$%&2100�� !(12)��

Hackett�� !"#$%2440�4260�� !"

�� !"#$(high altitude)(13)�� !"#$%

�� !"#$%&'()*+,'-./01

�� !"#$%&'()*+,-./01)

�� ! "#$%&'� (12-14)�� !"#

�� !"#(3952��) ��80.8%�� !"#

�� !"#3508�� !"#$79%�� !

�� !"#$%(2)�� !"#$%&'()*

�� !"#34.6%�� !"#$%&'()*

�� !3650�� !"#$%& #'()*

34%��(3)�� !"#$%&'()*+,-)

�� !"27%��(7)�� !"#$%&'()

�� !"#$%�&'(�)*!+,�-.

�� !"#$%&'()*+,-./012

�� !� "#$%&'()*+,-./0

�� !"#$%&'()*+,-./011

�� !"#$%&'(()*+,-./0'

�� 4�� !"#$%&1�3�� !!"#

�� 26�� !!"#!$%&'()

*��

�� !0 1 2 3 4 �� !" ��

�� 17 6 3 0 0 9 35%

�� 9 2 5 8 2 17 65%

�� 20 4 2 0 0 6 23%

�� 21 2 3 0 0 5 19%

�� 23 2 0 1 0 3 11%

�� ! 21 4 1 0 0 5 19%

�� ! 24 2 0 0 0 2 8%

�� 19 3 2 2 0 7 27%

�� 24 2 0 0 0 2 8%

�� ! 26 0 0 0 0 0 0%

�� 26 0 0 0 0 0 0%

�� 23 2 1 0 0 3 12%

�� 22 4 0 0 0 4 15%

* �� !"#$%&'0,1,2,3,4�� 0�� !"#$%1�� !"#$%&'()*+,2��

�� !"#$%&'(3�� !"#$%&'()$*+,-.4�� !"#$%&'()*

J Emerg Crit Care Med. Vol. 17, No. 2, 200650

�� !"#$%&'()*+,'-./01�

�� �!"#$%&'()(mean)�� !"#$% &'(median)�� !"#$%&'

�� !"#$%&'()$*+,-.%/01-23#456789#4:;<%-=9

�� ! �� (n�5) �� !(n�21) �� !"(n�9)

�� (2659��)

�� !"#$ -3�1.87 -5.19�2.04 -5.67�2.29

P-value 0.0199* 0.0470*

�� (3402��)

�� !"#$ -8.2�2.59 -11.57�4.32 -11�5.41

P-value 0.0550 0.3027

�� !(3952��)

�� !"#$ -10.4�3.78 -15.24�5.06 -16.33�6.12

P-value 0.0287* 0.0750

�� (3402��)

�� !"#$ -7.4�0.55 -11.62�4.92 -12�5.24

P-value 0.0005* 0.0303*

* P�0.05

51�� !"# $%&

�� !"#$%&'()*+,-./250��

�� !"#$%&'()*+,1400�2400�

�� !"#$%&'()* +,-. (15)�

2750�� !"#$%&!'()*(16)�� !

��2440-2745�� 25%�� !3�� !"#

�� !"5%�� !"#$%&'(10)�� !

�� 3050-3660�� !"#$%&'()*

�� !"10%�� !"#$%&'(10)��

�� 3,660�� !"#$%2%�� !"#$

�� (17)�� Hultgren H.�� 42�� !"

�� !"#$%&'12�(29%)�� !"#$

�� !"#$%&'()*+,-./012

��(10)�� !"#$%&'()*+,-./'

�� !"��� !"#$%&!'()*+,

�� !"#$% !&#$'()*+(18)��

�� !"#$%&'()*+,-.(19)����

��� !"#X�� !"#$%&'()*+,

(�� !"#��$!")�� !"#$%&

15%�� !"#$%&%'()��� 28.5%(19)�

�� !"#$%&'()*+,"-.91�7��

�� !"#$%&'()*+,94�3�� !

�� !"#�$%&'(()*+,-./0

�� !"#$%&'()*+,-./01.

�� !"#$%&'()*+',-./0"

�� !"#$%&'()*+,!"-./

��Hackett�� !"#$%50�� !"

�� !"#$%&'50�� !(13)�� Hult-

gren�� !"#$%�&'()*+,-./

�� (10)�� 3�� !"#$%&'()!*

�� !"#$%&'((20)�� !"#$%&

�� !"#$%&'()*+,-��./0

�� !"#$%&'()(21)�� !"#$%

�� !"#$%&'()*100�� !"#$

�� (3776��)(21)��70�� !"#$%&

�� !93�� !"4421�� !80�� !

�6000�� !"#$(21,22)�� !"#$%&'

�� !"#$%&'$%()$�*+,-.

�� !"#$%&'()*+,-(21)�� !

�� !"#$%&%'()*+,-'(14,23)��

�� !"#$%&'()*+,-./012

�� !"#$%$&'()%*+,-%

�� !"#$%&'()*+,-(10,12-14)��

�� !"#$%(�� )�� !"#$%&'

�� !"#$%&'()*+!,-./*0

�� !3:30��(morning call)�� !"#$%

��

�� !"#$%&'()*+,-.

(Hackett�s Acute Mountain Sickness Score,

HAMSS)�SpO2�� !"#$LLAMSS�SpO

2

�� !"(5)�� !"#$%&'()*+,)

�� !"#$%&'()*+,-./012

�� !"#$%&'()*+,-./012

�� SpO2�� !"#$%&'()*+�,

�� !"#$%&'()*+,-./012

�� !"#$%&'()�� *+,-!

�� !"#$%&'()*+,-./012

�� !"#$%&'()*+,-./012

�� !"#$%&'()*+,-5%�� !

�� 1%�� !"#$%&'()*+1.83

�� !�� !"#$%&'�()*+,-.

�� !"#$%&'()*+,-./0123

�� !"#$%&'()�*+,(10,12-14,24)� �

�� !"#$%&'($)*+,(24)�� !"

��2750�� !"#$%&'() (25)��

Hackett�� !"2500�� !"#$%&'(

�� !"#600��(14)�� !"#24�� !

�� !"#$%&'()*+,-./'01+23&�� !"#$%�

�� !"�� ! �� !"

* ‡OR (95%CI) OR (95%CI)

�� !"#$%& 0.601.83

0.692.00

(0.96, 3.50) (0.88, 4.55)

* �� !"#$%&'("#)*+,-‡OR=odds ratio (�� !")�CI=confidence interval (�� !)

J Emerg Crit Care Med. Vol. 17, No. 2, 200652

��3000�� !"#$%&'()*+,-.

�� !"#$�%&'()*+ 24�� !

�� 3402�� !"#$%&'()*+,-

�� !"#$%&'()%*+,-� !)

�� !"##$%&'!#()*+,-./

�� !"#$%&'()*+,-,./0#

�� !"#$%&''()"*+,(�� !

�� !"#$%&')�� !"!#$%!&

�� !"#$%&'()*+,-#./01

�� !"#$%&'()*+",-./0

�� !"#$%�&'()*+,�-./0

�� !"#$%&'()*+,-./

��

�� !"#$%&'()**+,)-.

�� !"#$%&'(34.6%�� !"#$%

��80.8%�� !"#$%&!'()*+,-

�� !84.19%�� !"#$%&'(%)#

�� !"#$%&'()*+,-./012

�� !"#$%&'()*+,-./012

�� !"#$%&'()*+,-./012

�� !"#$%&'()�*+,-./01

�� !"#5%�� !"#$1%�� !"#

�� !"#$% 1.83�� !"#$%&'(

�� !"#$%&'()*+,-./01

�� !"#$%$&'()*+,-.�/0

�� !"#$%&'()*� +,-./

�� !"#$%&'()*+,-./'01

�� !"#$%&'()*+,-./01!

�� !"#$%&'()*&'+!,-./

�� !

1.�� !"#$%&'()*+,-.,/!

�� !"#$%&'()�*+,-./0

�� !"#$%&'()*

2.�� !"#$%&'()*+,-./0

�� !"#$%&�'�()*+,-./

�� !"#$%&'()

3.�� !"#$%&'()*+,-./01

�� !"!#$%&'()*+,-

4.�� !"#$%&'()*+,-./0

�� !"#$%&'()*+,*-.�/

�� !"#$%&'()*+),-./

��

�� !"#$%&'()*+,-./0

�� !"#$%&'()*+,-+./01

�� !"#$%& �'()*+,-."#

�� !"#$%&'()*+,-./01"

�� !"#$%&'()*+,-./0(1

�� !"#$%&'( )*+,-./ 0

�� !"#$%&'()*+,-./012

�� !"#$%&'()*+,(-./01

��

�� !

1. Basnyat B, Murdoch DR. High-altitude illness.

Lancet 2003;361:1967-74.

2. Kamat S, Rao T, Sarma S, Venkataraman C,

Raju VR. Study of cardiopulmonary function

on exposure to high altitude. Am Rev Resp

Dis 1972;106:414-31.

3. Maggiorini M, Buhler M, Waiter M, Oelz O.

Prevalence of acute mountain sickness in the

Swiss Alps. BMJ 1990;301:853-5.

4.�� !"#$!"%&'(1999�� !"

�� !"#$%&'()*+,-./$0

�� !"#2000�2�34-45�

5. Roeggla G, Roeggla M, Podolsky A, Wagner

A, Laggner AN. How can acute mountain

sickness be quantified at moderate altitude. J

R Soc Med 1996;89:141-3.

6. Roach RC. Greene ER. Schoene RB. Hackett

PH. Arterial oxygen saturation for prediction

of acute mountain sickness. Avia Space Envi-

ron Med 1998;69:1182-5.

7. Wei-Fong Kao, Chien-Chun Kuo, Teh-Fu Hsu,

et al. Acute Mountain Sickness in Jade Moun-

tain Climbers of Taiwan. Avia Space Environ

53�� !"# $%&

Med 2002;73:359-62.

8.�� !"#$%&'()*+,!2004��

�� !"#$%&2004�15-26�

9. Roach RC, Bartsch P, Hackett PH, Oelz O.

The Lake Louise AMS Scoring Consensus

Committee. The Lake Louise actute mountain

sickness scoring system. In: Sutton JR, Coates

G, Huston CS, eds. Hypoxia and molecular

medicine: proceedings of the 8th international

hypoxia symposium, 9-13 Feb, 1993; Lake

Louise, Alberta, Canada. Burlington, VT: Queen

City Printers, 1993:272-4.

10. Hultgren H. Acute and subacute mountain

sickness. In: High altitude medicine, eds.

Stanford, California; Hultgren Publications,

1997:212-55.

11. Ge RL, Matsuzawa Y, Takeoka M. Kubo K,

Sekiguchi M, Kobayashi T. Low pulmonary

diffusing capacity in subjects with acute moun-

tain sickness. Chest 1997;111:58-64.

12. Rodway GW, Hoffman LA, Sanders MH.

High-al t i tude-re la ted disorders--par t I :

Pathophysiology, differential diagnosis, and

treatment. Heart & Lung 2003;32:353-9.

13. Hackett PH. High-altitude medical problems.

Emergency medicine-A comprehensive study

guide, 6th ed. JE, Tintinalli. McGraw Hill CO.

USA. 2004;1262-71.

14. Hachett PH, Roach RC. High Altitude Illness.

N Engl J Med 2001;345:107-14.

15. Gabry AL, Ledoux X, Mozziconacci M, MartinC.

High-altitude pulmonary edema at moderate

altitude (<2400 m;7870 feet): a series of 52

patients. Chest 2003;123:49-53.

16. Hultgren H. High altitude cerebral edema. In:

High Altitude Medicine, Hultgren H, ed.

Stanford, California; Hultgren Publications,

1997:321-47.

17. Bezruchka S. High altitude medicine. Medical

Clinics of North America 1992;76:1481-97.

18. �� !"#$!%&'(�)*(+,-

��1995�36�35-50�

19. ��� !"# $%&'()*+,-./0

�� !�"#$%&'()*+,-./01

�� !"#$%&'()*+2004�7��

20. Yaron M, Waldman N, Niermeyer S, Nicholas

R, Honigman B. The diagnosis of acute moun-

tain sickness in preverbal children. Arch Pedi-

atr Adolesc Med 1998;152:683-7.

21. Hultgren H. Miscellaneous sea level conditions.

In: High Altitude Medicine, Hultgren H, ed.

Stanford, California; Hultgren Publications,

1997:465-71.

22. Rodway GW, Hoffman LA, Sanders MH.

High-altitude-related disorders-Part II: Prevention,

special populations, and chronic medical

conditions: Heart & Lung 2004;33:3-12.

23. Hultgren H. Women and altitude In: High

Altitude Medicine, eds. Stanford, California;

Hultgren Publications 1997:472-84.

24. Barry PW, Pollard AJ. Altitude illness. BMJ

2003;326:915-9.

25. Hultgren H. High altitude pulmonary edema.

In: High Altitude Medicine, Hultgren H, ed.

Stanford, California; Hultgren Publications,

1997: 256-320.

J Emerg Crit Care Med. Vol. 17, No. 2, 200654

Predicting Acute Mountain Sickness Susceptibility in JadeMountain Climbers by Oxygen Saturation at Mountain

Entrance and Sea-level

WEI-CHUN KAO1,2, CHUEN-DEN TSENG1,3, HSIU-SI CHEN1, HUI-MING MA4, JIN-JONG CHEN5,7, WEI-FONG KAO6,7

Objective: To examine acute mountain sickness (AMS) in Jade mountain climbers using oxygen satura-tion (SpO

2) at different altitudes.

Methods: Twenty-six climbers (12 female, 14 male) aged 29 to 70 years (mean 45.88±9.7) were enrolled.All lived below 1 km. AMS was diagnosed using the Lake Louise Consensus. A climber with at least onehigh altitude symptom was defined as having high altitude syndrome (HAS). Levels of SpO

2 and answers to

AMS questionnaires were recorded at different altitudes.Results: The most common high altitude symptom was insomnia, then headache and nausea. The HAS

and AMS prevalence rates were 80.8% and 34.6%, respectively. The average SpO2 level at Jade Mountain

peak was 84.19±5.39%. The lower the SpO2 level at the entrance of Jade Mountain (2659 m), the higher

the Lake Louise AMS score (LLAMSS) (r=-0.215, P=0.047). The greater decline in SpO2 level between the

entrance of Jade Mountain and sea-level, the greater the risk of HAS (� 1.8) and AMS (� 2.0).Conclusions: A large decline in SpO

2 level between the entrance of Jade Mountain and sea-level

positively correlated with the incidence rates for HAS and AMS.

Key words: acute mountain sickness, oxygen saturation, Jade Mountain, high altitude syndrome

Received: April 28, 2005 Accepted for publication: November 28, 2005From the 1Institute of Preventive Medicine, College of Public Health, National Taiwan University,2Medical Affairs Division, Department of Health of Taipei City Government,3Department of Internal Medicine, National Taiwan University Hospital,4Department of Emergency Medicine, National Taiwan University Hospital, Section of Emergency Medicine, National Taiwan University,5Sport Medicine Research Center, National Yang-Ming University, Taipei, Taiwan,6Department of Emergency Medicine, Veterans General Hospital, andSection of Emergency Medicine, National Yang-Ming University, Taipei, Taiwan,

7Taipei City HospitalAddress for reprints: Dr. Wei-Fong Kao, 201 Shih-Pai Road, Section 2, Taipei 112, Taiwan, R.O.C.Department of Emergency Medicine, Veterans General Hospital-Taipei.Tel: (02) 28757628 Fax: (02) 28757842E-mail: wfkao@vghtpe.gov.tw